Matches in DBpedia 2015-10 for { ?s ?p "Debiopharm Group (Debiopharm) is a global biopharmaceutical group of companies comprising Debiopharm S.A., Debio R.P. S.A. (Recherche Pharmaceutique), Debioclinic S.A. and the two financial arms Debiomanagement S.A. and Debioinnovation S.A. The group applies scientific and clinical expertise to address unmet medical needs through the in-licensing of promising biologics and small molecules, the clinical development of the same and the out-licensing for commercialiasation. The group is family owned. The company has developed triptorelin under the brandnames Decapeptyl/Trelstar/Pamorelin for the palliative treatment of advanced prostate cancer, endometriosis, uterine fibromyomas, precocious puberty, female infertility, breast cancer and ovarian cancer, and under the brandnames Moapar/Salvacyl for the treatment of severe sexual deviations and of oxaliplatin (Eloxatin/Elplat) for the treatment of colorectal cancer. For thirty years Debiopharm Group has established alliances with leading biotech, pharmaceutical and start-up companies as well as with academic institutions. Sanofi-Aventis, Ipsen Pharma, Novartis, Curis, MSM Protein Technologies, Mercury Therapeutics, École Polytechnique Fédérale de Lausanne (EPFL) are a few examples of Debiopharm partners."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- Debiopharm abstract "Debiopharm Group (Debiopharm) is a global biopharmaceutical group of companies comprising Debiopharm S.A., Debio R.P. S.A. (Recherche Pharmaceutique), Debioclinic S.A. and the two financial arms Debiomanagement S.A. and Debioinnovation S.A. The group applies scientific and clinical expertise to address unmet medical needs through the in-licensing of promising biologics and small molecules, the clinical development of the same and the out-licensing for commercialiasation. The group is family owned. The company has developed triptorelin under the brandnames Decapeptyl/Trelstar/Pamorelin for the palliative treatment of advanced prostate cancer, endometriosis, uterine fibromyomas, precocious puberty, female infertility, breast cancer and ovarian cancer, and under the brandnames Moapar/Salvacyl for the treatment of severe sexual deviations and of oxaliplatin (Eloxatin/Elplat) for the treatment of colorectal cancer. For thirty years Debiopharm Group has established alliances with leading biotech, pharmaceutical and start-up companies as well as with academic institutions. Sanofi-Aventis, Ipsen Pharma, Novartis, Curis, MSM Protein Technologies, Mercury Therapeutics, École Polytechnique Fédérale de Lausanne (EPFL) are a few examples of Debiopharm partners.".